Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC24H29ClF2N2O3 |
InChIKeyYIIMJZMCUAOYKW-QZTJIDSGSA-N |
CAS Registry3055744-21-0 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | United States | 24 Dec 2024 |